Direkt zum Inhalt
Merck
  • Lidocaine-prilocaine (EMLA(®) ) cream as analgesia in hysteroscopy practice: a prospective, randomized, non-blinded, controlled study.

Lidocaine-prilocaine (EMLA(®) ) cream as analgesia in hysteroscopy practice: a prospective, randomized, non-blinded, controlled study.

Acta obstetricia et gynecologica Scandinavica (2013-06-07)
Baldomero Arnau, Esther Jovell, Stephanie Redón, Marta Canals, Vanessa Mir, Elena Jiménez
ZUSAMMENFASSUNG

We investigated the efficacy of 5% lidocaine 25 mg-prilocaine 25 mg/g cream (EMLA(®) ) applied to the uterine cervix for reducing pain during diagnostic or operative hysteroscopy, using a visual analogue scale (VAS) for pain in a prospective randomized, non-blinded, controlled study in 92 successive patients. Patients were randomized to either 3 mL of EMLA cream or 3 mL of ultrasound gel (placebo), placed endocervically and exocervically, 10 min before hysteroscopy. Intensity of pain was evaluated immediately after the procedure using a 10-cm VAS. No differences were found between the two groups (p = 0.07). The number of women who wished to stop the procedure was significantly lower in the EMLA group compared with the control group (p = 0.013). We concluded that topical instillation of EMLA does not decrease pain during hysteroscopy, but does reduce a desire to abandon the procedure.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Lidocainhydrochlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lidocain, powder
Supelco
Lidocain, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lidocain -hydrochlorid Monohydrat, solid
Sigma-Aldrich
Lidocain, analytical standard
Lidocainhydrochlorid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Prilocain -hydrochlorid, ≥98% (TLC)
Lidocain, European Pharmacopoeia (EP) Reference Standard